Winona LaDuke argues in her Oct. 10 commentary that despite the defeat suffered by opponents of the recent completion of Enbridge's Line 3 replacement pipeline, their strategies have been affirmed and the defeat offset by other victories ("Line 3 opponents can savor this defeat," Opinion Exchange).
She claims that "no one wants to finance more tar sands" because of low oil prices and the four-year delay in opening the pipeline. But what was $50-a-barrel oil then is over $80 a barrel now and rising daily, and the pipeline is now up and running at twice the capacity of the old one.
She's also pleased that Harvard University has begun divesting itself of fossil fuel holdings. But wouldn't it be better for concerned investors to hold onto their investments and use that leverage to lobby for positive change, which has shown some recent success? If Harvard's holdings are instead held by private equity firms, will they push as hard to phase out fossil fuels?
I've always wondered if the pipeline's opponents ever considered negotiating a replacement that ran along the old route but would have kept the flow at the half-capacity required by the aging original line. By holding out for total victory, they've ended up with a pipeline that has to follow a much longer route and will be pumping at twice the capacity for years to come.
Sometimes, moral victories might not be as valuable as they seem.
Bruce Williams, New Brighton
MEDICAL COSTS
Poor Big Pharma, just scraping by with zillions to spare
Annette Thompson Meeks, in her commentary "Side effects of voiding drug patents would be severe" (Opinion Exchange, Oct. 19), claims that the loss of patents on vaccines would result in the pharmaceutical industry and investors foregoing billions of dollars of research and development aimed at new and better medicines. Meeks neglects to mention that companies such as UnitedHealth Group have made high profits in the past year, and handed a $42 million package to its outgoing CEO.
Meeks repeats the usual claim that the industry spends an enormous amount of money in research and development but that it accepts this cost due to the generous patent protections on new medications, including vaccines. Well, yes, but she also neglects a study by the Institute for Health and Socio-Economic Policy showing that of the top 100 drug companies by sales, 64 spent twice as much on marketing and sales as they did on research and development. Indeed, 58 spent three times as much, 43 spent five times as much, and 27 spent 10 times as much!